Clinical trialsCompany release

Immatics expects to finish SUPRAME randomisation by year-end, with anzu-cel BLA planned for 2027

Immatics N.V. (IMTX) · Tue 10 Nov 2026

The cell therapy developer reported Q3 2026 results, with Phase 3 melanoma data due in H1 2027 and cash of $536.3 million funding operations into Q4 2028.

Immatics N.V. said on 10 November 2026 that randomisation in its Phase 3 SUPRAME trial should be complete by the end of the year. The study is testing anzu-cel (IMA203) in previously treated advanced melanoma.

The company expects topline progression-free survival (PFS) data in the first half of 2027. A Biologics License Application (BLA) to the US Food and Drug Administration is planned to follow later in 2027.

Alongside its third-quarter results, Immatics presented updated Phase 1 data at ESMO 2026 for two other programmes: IMA203CD8 and the IMA402 bispecific. The summary available does not include the details of those datasets.

Immatics reported cash of $536.3 million, which it projects will fund operations into the fourth quarter of 2028. The full text of the company's announcement was not available, so further financial and clinical details are not covered here.

What it means for your team

  • Regulatory teams tracking cell therapies in melanoma should note the sequence: SUPRAME PFS topline in H1 2027, then a BLA submission to the FDA in 2027.
  • Completion of randomisation by year-end is the next trial milestone to watch; any change to that timing would affect the data and filing schedule.
  • Market-access and competitive-intelligence teams may wish to follow the ESMO 2026 Phase 1 updates for IMA203CD8 and IMA402, as the full data were not covered in the material reviewed.

Company's press release (SEC filing): Immatics N.V. ↗

Article written by VigiEye from the official source (Immatics N.V.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →